U.S. ex rel. Pepe M.D. and Sherman, M.D. v. Fresenius Vascular Care, Inc., et al.
In 2022, the federal government and multiple state governments intervened in this qui tam action commenced by Cohen Milstein on behalf of the whistleblowers against Fresenius Vascular Care, Inc. and affiliated defendants, alleging that they violated the federal and state False Claims Acts by performing and billing Medicare and Medicaid for unnecessary surgical procedures that were not covered by these programs, that subjected patients to health risks, and that defrauded the government and taxpayers of many millions of dollars. The action seeks treble damages and civil penalties.
U.S.A. v. Janssen Biotech, Inc.
U.S.A. v. Janssen Biotech, Inc. (D. Mass.): Cohen Milstein represents the plaintiff-relator in a whistleblower/qui tam lawsuit against Janssen Biotech (a subsidiary of Johnson & Johnson), alleging that the manufacturer of the rheumatoid arthritis drugs Remicade and Simponi ARIA violated federal law by engaging in a scheme through which it provided physicians free practice management and infusion business consulting services over an extended period to induce the physicians to purchase Remicade and Simponi ARIA and administer these drugs to patients, including Medicare beneficiaries, via infusions performed in their offices.